Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. reports biotechnology developments centered on emavusertib (CA-4948), an orally available small-molecule IRAK4 and FLT3 inhibitor. Company updates focus on oncology programs in lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia, including clinical data presentations, combination approaches with BTK inhibitors, and studies involving venetoclax and azacitidine.
Recurring Curis news also covers quarterly financial and operating results, conference-call updates, capital actions such as private placements, and security-structure matters involving preferred stock and warrants. The company’s public updates combine clinical-program progress with financing, governance and operating disclosures typical of a development-stage biotechnology issuer.
Curis, a biotechnology company listed on NASDAQ under the ticker CRIS, announced that its President and CEO, James Dentzer, will present at the Jones Healthcare Seaside Summit 2024. The presentation is scheduled for July 15, 2024, at 8:00 a.m. PT (11:00 a.m. ET). Curis focuses on developing emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor. A live webcast and an archived replay of the presentation will be accessible through the Events & Presentations section of Curis's website.
Curis announced that its independent Compensation Committee approved an inducement stock option grant for a new employee. The grant, effective July 1, 2024, allows the employee to purchase 25,000 shares of Curis common stock at the closing price on the grant date. The stock options have a 10-year term and vest over four years, with 25% vesting after the first year and 6.25% vesting every three months thereafter. This grant is outside of the company's existing stock incentive plan and aims to encourage the new employee to join Curis.
Curis announced updated data from its ongoing TakeAim Leukemia study, focusing on emavusertib (CA-4948) treatment for relapsed/refractory AML patients with FLT3 and U2AF1/SF3B1 mutations. The dataset increased from 5 to 30 patients, showing 6 objective responses in 11 FLT3m patients and 4 in 18 SFm patients. Notable responses included complete remission and morphologic leukemia-free state. The data also highlighted increased neutrophil counts in several ongoing patients, indicating potential clinical benefits. These findings will be presented at the ASCO and EHA conferences.
Curis, Inc. (NASDAQ: CRIS) will present updated data from the TakeAim Leukemia study on May 14, 2024. The company focuses on emavusertib (CA-4948), an IRAK4 inhibitor. A conference call will follow the presentation.
Curis, Inc. (NASDAQ: CRIS) provided a business update and financial results for Q1 2024. The company will present clinical data on emavusertib for leukemia patients, updated data for R/R AML, and upcoming milestones for ongoing studies. Financially, Curis reported a net loss of $11.9 million, a decrease in revenue, and increased R&D and G&A expenses. Cash, cash equivalents, and investments totaled $40.7 million as of March 31, 2024.
Curis, Inc. (NASDAQ: CRIS) will release its first quarter 2024 financial results on May 7, 2024, followed by a conference call. The company is focused on developing emavusertib (CA-4948), an IRAK4 inhibitor. Investors can access the call via phone or the company's website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.